Laflunimus

SKU: orb1709283

Description

Laflunimus

Research Area

Cell Biology, Immunology & Inflammation, Metabolism Research, Molecular Biology, Pharmacology & Drug Discovery

Key Properties

• CAS Number: 147076-36-6
• MW: 310.27
• Purity: 99.86% (May vary between batches)
• Formula: C₁₅H₁₃F₃N₂O₂
• SMILES: N(C(/C(=C(\O)/C1CC1)/C#N)=O)C2=CC(C)=C(C(F)(F)F)C=C2
• Target: Prostaglandin Receptor,Dehydrogenase,DNA/RNA Synthesis
• Solubility: 10% DMSO+90% Corn Oil:2 mg/mL (6.45 mM);DMSO:40 mg/mL (128.92 mM)

Bioactivity

• Target IC50:
  IgG secretion with 50 μM uridine:60 μM|IgM secretion with 50 μM uridine: 70 μM|IgM secretion from LPS-stimulated mouse splenocytes: 2.5 μM|IgG secretion from LPS-stimulated mouse splenocytes: 2.0 μM
  Read more...
• In Vivo:
  Laflunimus inhibited the secondary antibody response to sheep red blood cells (SRBC) in mice, with an ID₅₀ of 38 mg/kg orally. Co-administration of uridine reversed immunosuppression induced by Laflunimus (50 mg/kg), whereas uridine alone had no effect and did not reverse immunosuppression caused by cyclophosphamide (10 mg/kg).
  Read more...
• In Vitro:
  Laflunimus (HR325) inhibited LPS-induced IgM and IgG secretion from mouse splenocytes, with IC₅₀ values of 2.5 μM and 2 μM, respectively. The addition of exogenous uridine (50 μM) reversed this effect, increasing the IC₅₀ values to 70 μM for IgM and 60 μM for IgG, suggesting a pyrimidine depletion mechanism. Laflunimus also suppressed LPS-induced κ light-chain surface expression in 70Z/3 cells, which was similarly reversed by uridine.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

HR325, HR-325, HR 325, Laflunimus

Compound Identifiers

PubChem CID

54684599